Rejected from Lancet Neurology? Where to Submit Next

The useful question is not "which neurology journal is easier?" It is "what did Lancet Neurology not believe about this manuscript?"

If the editor did not believe the work would change clinical neurology understanding or management for a broad readership, the next journal should probably be more disease-specific, more mechanistic, more psychiatric, or more general clinical. If the editor believed the clinical question mattered but the evidence package was thin, then moving journals without repair is risky. If reviewers questioned endpoint choice, subgroup logic, sample size, comparator, registration, reporting, or interpretation, those problems travel with the manuscript.

Use the decision letter to classify the failure:

Lancet Neurology is not a normal neurology step in a prestige ladder. The source-backed fit screen is different. The journal's public positioning is broad clinical neurology with global practice and policy relevance. ScienceDirect also reports 5 days to first decision, 39 days to decision after review, 43 days to acceptance, and 47 days from acceptance to online publication on the journal page, which means many submissions are filtered before authors get a long reviewer report.

That makes the rejection diagnostically useful. It often means one of three things:

• The paper is good but too subspecialist for the journal. A strong epilepsy, stroke, movement-disorder, dementia, neuroimmunology, neuromuscular, imaging, or rehabilitation paper can still be strongest in a specialist venue.
• The clinical consequence is implied rather than proven. The paper has a credible dataset, but the abstract does not say what neurologists should diagnose, treat, monitor, counsel, or stratify differently.
• The evidence hierarchy is unstable. The manuscript uses a surrogate endpoint, exploratory subgroup, biomarker association, imaging marker, or secondary analysis to support a practice-level claim.

This is why the next submission should be routed by manuscript phenotype, not by impact-factor adjacency.

This page was researched from official Lancet Neurology author material, the journal's public about and submission pages, ScienceDirect's journal page, and Manusights' existing Lancet Neurology content cluster. In our analysis of the post-rejection routing job, the non-obvious question is not whether Brain, Neurology, or JAMA Neurology is "next." It is which manuscript component created the rejection signal: title, abstract, primary endpoint, patient population, comparator, statistics, first figure, reporting checklist, cover letter, or limitations.

The specific rejection patterns below are written as a diagnostic, not as a generic list. We see authors lose time when they interpret a Lancet Neurology rejection as a status problem, but the paper actually has a clinical-consequence, endpoint, or audience problem. In practice, the best next journal is the one where the manuscript's evidence can support its claim without forcing a broader clinical-neurology story than the data can carry.

Rebuild for Lancet Neurology only when the manuscript still has a flagship clinical-neurology claim and the rejection exposed a repairable weakness. This is most plausible after a detailed review, a revision decision, or a desk rejection where the evidence is strong but the clinical story was buried.

Good reasons to rebuild:

• The primary finding changes diagnosis, prognosis, treatment, monitoring, counseling, stratification, trial design, or guideline interpretation across more than one setting.
• The rejection letter questioned presentation, emphasis, reporting completeness, or fit argument rather than the underlying study question.
• The methods package can be strengthened with a reporting checklist, sensitivity analysis, subgroup discipline, registration clarity, or clearer endpoint hierarchy.
• The strongest clinical consequence was hidden in the discussion instead of visible in the title, abstract, results, first figure, and cover letter.

Bad reasons to rebuild:

• You only want to stay near the Lancet brand.
• The study is an exploratory biomarker, imaging, or subgroup analysis framed as a clinical-practice change.
• The manuscript is disease-specialist work whose best readers are not broad clinical neurologists.
• The core limitation requires new data, longer follow-up, or a different trial design.

If you rebuild, make the correction visible early. A new cover letter alone cannot rescue an endpoint hierarchy that still overclaims.

Brain is often the better next journal when the rejected paper has deep disease biology or mechanistic strength. A manuscript that is too mechanistic for Lancet Neurology can be strong for Brain if the disease logic, human relevance, and biological insight are substantial.

Choose Brain when the manuscript can answer:

• What does this teach about disease mechanism, pathophysiology, neurobiology, or disease progression?
• Does the clinical cohort, model, imaging, genetics, pathology, or biomarker evidence explain a neurological disease in a durable way?
• Is the mechanistic contribution as strong as the clinical relevance?
• Would the paper still matter if the immediate treatment or management implication were modest?

If the answer is mostly "this changes how neurologists manage patients," Brain may not be the best target. Neurology, JAMA Neurology, Annals of Neurology, or a disease-specialist journal may fit better.

Many Lancet Neurology rejections are still strong clinical neurology papers. They simply do not clear the Lancet-level breadth or policy threshold.

Move toward Neurology when the paper is practical for neurologists: diagnosis, prognosis, treatment decision, management, counseling, care pathway, or clinical risk stratification. Move toward JAMA Neurology when the study is methodologically clean and broad enough for a high-visibility clinical audience. Move toward Annals of Neurology when the study combines clinical relevance with translational or disease-mechanism depth.

The rewrite should be honest about reach. A paper can be useful without claiming to change global neurology practice. Make the action specific: which clinician, trialist, guideline reader, disease specialist, or patient-care team can use the result.

If the rejected manuscript is mainly about one disease niche, one technique, one cohort, one biomarker, one imaging method, or one preclinical mechanism, the next journal should follow the scientific center of gravity.

The clearest warning sign is a clinical abstract wrapped around evidence that is actually mechanistic, exploratory, or subspecialist. Lancet Neurology may reject because the manuscript cannot prove a broad clinical consequence. A disease-specialist or neuroscience journal can be stronger if the paper's real contribution is narrower but deeper.

Before submitting again, rewrite the title, abstract, and conclusion so they match the actual evidence. A biomarker paper should state whether it supports diagnosis, prognosis, stratification, or mechanism. An imaging paper should separate measurement novelty from clinical utility. A preclinical paper should not promise patient-management change unless the evidence directly supports it.

In our pre-submission and post-decision review work with manuscripts aimed at Lancet Neurology, the highest-value repairs are usually not language edits. They are routing and evidence-hierarchy decisions tied to concrete components: title, abstract, endpoint table, trial registration, cohort definition, comparator, statistical model, figure order, reporting checklist, cover letter, and limitations.

Three specific rejection patterns are especially common.

The hidden clinical-consequence gap. The manuscript has rigorous neurology data, but the clinical implication appears late or indirectly. The title names a disease or method, the abstract reports an association, and the discussion finally claims practice relevance. For Lancet Neurology, the clinical consequence needs to be legible early: diagnosis, treatment, prognosis, monitoring, counseling, stratification, or guideline interpretation. The repair is not hype. The repair is to state the exact patient-care or neurology-interpretation decision that the evidence supports.

The endpoint-hierarchy gap. The paper uses a secondary endpoint, exploratory subgroup, surrogate biomarker, imaging marker, or post hoc analysis as if it were the primary evidence for a broad clinical claim. Editors and reviewers notice this quickly because a clinical-neurology journal cannot let exploratory evidence carry a practice-level conclusion. The repair is to rebuild the claim around the primary endpoint, mark exploratory findings as exploratory, and choose a journal where that level of evidence is acceptable.

The wrong-audience gap. The best readers for the paper are not the readers implied by Lancet Neurology. A disease-specialist paper is framed as broad neurology. A mechanistic neuroscience paper is framed as clinical practice. A psychiatry-overlap paper is framed as general neurology. These manuscripts often improve after rejection because the next submission finally names the correct audience and writes for that audience.

The practical lesson is direct: after Lancet Neurology rejection, the manuscript should either become a stronger flagship clinical-neurology paper or a more honest paper for a better-matched journal. The worst option is a cosmetic resubmission that preserves the same unsupported clinical claim.